Alexion Pharmaceuticals (NASDAQ:ALXN) Releases FY19 Earnings Guidance

Alexion Pharmaceuticals (NASDAQ:ALXN) updated its FY19 earnings guidance on Wednesday. The company provided earnings per share (EPS) guidance of $10.25-10.40 for the period, compared to the Thomson Reuters consensus estimate of $9.93. The company issued revenue guidance of $4.86-4.89 billion, compared to the consensus revenue estimate of $4.84 billion.Alexion Pharmaceuticals also updated its FY 2019 guidance to $10.25-10.40 EPS.

Several equities research analysts have recently commented on the stock. BMO Capital Markets assumed coverage on shares of Alexion Pharmaceuticals in a report on Thursday, September 12th. They issued an outperform rating and a $149.00 price target for the company. ValuEngine raised shares of Alexion Pharmaceuticals from a strong sell rating to a sell rating in a research report on Wednesday, October 2nd. Cowen reaffirmed a buy rating and issued a $165.00 price objective on shares of Alexion Pharmaceuticals in a research report on Wednesday, October 16th. Piper Jaffray Companies set a $180.00 price objective on shares of Alexion Pharmaceuticals and gave the stock a buy rating in a research report on Friday, September 6th. Finally, JPMorgan Chase & Co. initiated coverage on shares of Alexion Pharmaceuticals in a research report on Wednesday, July 31st. They issued an overweight rating and a $172.00 price objective on the stock. One investment analyst has rated the stock with a sell rating, five have given a hold rating and fifteen have given a buy rating to the company. The company has a consensus rating of Buy and a consensus price target of $159.76.

NASDAQ ALXN traded down $0.99 on Thursday, hitting $105.64. 76,908 shares of the company’s stock traded hands, compared to its average volume of 1,689,730. The company has a current ratio of 4.04, a quick ratio of 3.56 and a debt-to-equity ratio of 0.26. Alexion Pharmaceuticals has a 1-year low of $92.56 and a 1-year high of $141.86. The firm’s 50-day moving average price is $101.73 and its two-hundred day moving average price is $117.93. The firm has a market capitalization of $22.26 billion, a PE ratio of 14.87, a P/E/G ratio of 0.97 and a beta of 1.67.

Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its quarterly earnings data on Wednesday, October 23rd. The biopharmaceutical company reported $2.79 EPS for the quarter, beating the consensus estimate of $2.47 by $0.32. Alexion Pharmaceuticals had a net margin of 29.64% and a return on equity of 20.23%. The business had revenue of $1.26 billion during the quarter, compared to analysts’ expectations of $1.24 billion. During the same period in the previous year, the business posted $2.02 EPS. The business’s quarterly revenue was up 23.0% compared to the same quarter last year. On average, research analysts anticipate that Alexion Pharmaceuticals will post 9.06 earnings per share for the current fiscal year.

About Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and Soliris (eculizumab), a monoclonal antibody for the treatment of PNH, atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis.

See Also: Return on Investment (ROI) Defined, Explained

Earnings History and Estimates for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.